Global Infectious Diseases Market, By Product and Services (Assays, Kits and Reagents, Instruments, Services and Software), Technology (Immunodiagnostics, Clinical Microbiology, Polymerase Chain Reaction (PCR), Isothermal Nucleic Acid Amplification Technology (INAAT), DNA Sequencing and Next-Generation Sequencing (NGS), DNA Microarray, Other Technologies), Disease Type (Hepatitis, Human Immunodeficiency Virus (HIV), Chlamydia Trachomatis Genital Infection and Gonorrhea (CT/NG), Hospital-Acquired Infections (HAIS), Human Papillomavirus (HPV), Tuberculosis (TB), Influenza, Other Infectious Diseases), End User (Hospital/Clinical Laboratories, Reference Laboratories, Physician Offices, Academic/Research Institutes, Other End Users) – Industry Trends and Forecast to 2029.
Infectious Diseases Market Analysis and Size
According to the Australian Institute of Health and Welfare, the NNDSS received approximately 593,000 cases of notifiable diseases in 2019. In addition, the almost 447,000 hospitalizations for communicable diseases in 2017–18, 89 percent were caused by non–notifiable infections. The hospitalisation rate for non-notifiable communicable diseases peaked during 2000-01 and 2017-18 at 15.3 per 1,000 people in 2016-17. (nearly 400,000 hospital separations).
Data Bridge Market Research analyses that the infectious disease market which was USD 18.34 billion in 2021, would rocket up to USD 28.73 billion by 2029, and is expected to undergo a CAGR of 5.77% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Infectious Diseases Market Scope and Segmentation
2022 to 2029
2020 (Customizable to 2014 - 2019)
Revenue in USD Billion, Volumes in Units, Pricing in USD
Product and Services (Assays, Kits and Reagents, Instruments, Services and Software), Technology (Immunodiagnostics, Clinical Microbiology, Polymerase Chain Reaction (PCR), Isothermal Nucleic Acid Amplification Technology (INAAT), DNA Sequencing and Next-Generation Sequencing (NGS), DNA Microarray, Other Technologies), Disease Type (Hepatitis, Human Immunodeficiency Virus (HIV), Chlamydia Trachomatis Genital Infection and Gonorrhea (CT/NG), Hospital-Acquired Infections (HAIS), Human Papillomavirus (HPV), Tuberculosis (TB), Influenza, Other Infectious Diseases), End User (Hospital/Clinical Laboratories, Reference Laboratories, Physician Offices, Academic/Research Institutes, Other End Users)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered
Abbott (U.S.), BD (U.S.), bioMérieux (France), Bio-Rad Laboratories Inc. (U.S.), Danaher (U.S.), DiaSorin S.p.A. (Italy), Meridian Bioscience Inc. (U.S.), Quidel Corporation (U.S.), Siemens (Germany), Thermo Fisher Scientific Inc. (U.S.), Johnson and Johnson Private Limited (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Cepheid (U.S.), Qiagen (Germany), OraSure Technologies, Inc. (U.S.)
Infectious diseases are disorders caused by microbes such bacteria, viruses, fungi, or parasites. Most of the time, they are advantageous or even secure. But under specific circumstances, some bacteria can potentially lead to disease. Some contagious diseases have the potential to spread from person to person. Others are spread by animals or insects.
Infectious Diseases Market Dynamics
- Increasing demand of personalised medicines
The development of genomics and proteomics is anticipated to boost market expansion. In the forecast period of 2022 to 2029, it is anticipated that additional factors such as rising government-funded programmes, rising shift from centralised laboratories to decentralised point-of-care testing, and rising demand for personalised medicines will boost the market for infectious disease testing products.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the market growth rate is the rising healthcare expenditure which helps improve its infrastructure. Also, various government organizations aim to improve the healthcare infrastructure by increasing funding, which will further influence the market dynamics.
- Rise in the geriatric population
The rising prevalence rates of lifestyle disorders like rising health-care spending, and the fast-growing diagnostic industry are driving the infectious disease market expansion. In addition, the growing elderly population, increased demand for laboratory automation, and more awareness of preventative healthcare are all driving the infectious disease market forward.
- Increase in the number of research and development activities
The increased prevalence of infectious diseases around the world is driving the global market for infectious disease. Furthermore, the expansion of the market during the forecast period is anticipated to be fuelled by investments in healthcare infrastructure made by governments all over the world. Additionally, it is anticipated that an increase in research and development activities in the healthcare industry will support market growth over the next years.
- High cost
On the other hand, unfavourable reimbursement policies of the insurance companies along with high cost of healthcare restrains the market growth. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the market.
This infectious diseases market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the infectious diseases market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Infectious Diseases Market
The global market for infectious disease is expected to expand as a result of the COVID-19 outbreak. The global healthcare systems have been under pressure due to the COVID-19 pandemic, which has increased the demand for diagnostic tools and diagnostic service facilities. The need for real-time polymerase chain reaction (RT-PCR) tests to detect COVID-19 increased as the number of COVID-19 patients increased. COVID-19 has led to the development of a number of novel, highly accurate, and cost-effective testing techniques. In order to assure the supply of testing kits in the healthcare industry, the Association of British HealthTech Industries (ABHI), BioIndustry Association (BIA), and the British In-Vitro Diagnostic Association (BIVDA) stated a global requirement for testing kit components on April 1, 2020. In order to determine who is affected by COVID-19, mass testing is carried out in South Korea. Additionally, lab tests are more accurate than testing kits. The producers are concentrating their efforts on creating sophisticated testing kits and using fresh approaches to save costs and win government approval.
- On March 18, 2020, The Food and Drug Administration (FDA) granted Abbott emergency use permission (EUA) for their molecular test to identify SARS-CoV-2, the virus that causes COVID-19. Approximately 150,000 laboratory tests will be conducted right away by the company.
- On March 31, 2020, Becton Dickinson and Company (BD) announced the release of a new Rapid Serology Test to identify COVID-19 exposure. The procedure is a new point-of-care test that can identify present or previous exposure to COVID-19 in less than 15 minutes by detecting antibodies in blood.
Global Infectious Diseases Market Scope
The infectious disease market is segmented on the basis of product and services, technology, disease type, and end-users. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product and Services
- Services and Software
- Clinical Microbiology
- Polymerase Chain Reaction
- Isothermal Nucleic Acid Amplification Technology
- DNA Sequencing and Next-Generation Sequencing
- DNA Microarray
- Other Technologies
- Human Immunodeficiency Virus
- Chlamydia Trachomatis Genital Infection and Gonorrhea
- Hospital-Acquired Infections
- Human Papillomavirus
- Hospitals/clinical laboratories
- Reference laboratories
- Physician offices
- Academic/research institutes
- Other end-users
Infectious Diseases Market Regional Analysis/Insights
The infectious diseases market is analysed and market size insights and trends are provided by country, product type, application and end-user as referenced above.
The countries covered in the infectious diseases market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the infectious diseases market due to the high prevalence of improved healthcare infrastructure, increasing occurrences of infectious diseases, adoption of advanced technology, and rising number of clinical laboratories.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to the rising health awareness among the people and growing demand of advanced medical technology.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Infectious Diseases Market Share Analysis
The infectious diseases market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to infectious diseases market.
Some of the major players operating in the infectious diseases market are:
- Abbott (U.S.)
- BD (U.S.)
- bioMérieux (France)
- Bio-Rad Laboratories Inc. (U.S.)
- Danaher (U.S.)
- DiaSorin S.p.A. (Italy)
- Meridian Bioscience Inc. (U.S.)
- Quidel Corporation (U.S.)
- Siemens (Germany)
- Thermo Fisher Scientific Inc. (U.S.)
- Johnson and Johnson Private Limited (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Cepheid (U.S.)
- Qiagen (Germany)
- OraSure Technologies, Inc. (U.S.)